CS
We recommend offering BRRS cases with a mutation in PTEN the same surveillance protocol for (malignant) tumours as is currently recommended for CS.
We recommend offering BRRS cases with a mutation in <span class="gene" id="14574156-10-52-56">PTEN</span> the same surveillance protocol for (malignant) tumours as is currently recommended for <span class="disease" id="14574156-10-144-146">CS</span>.